Passage Bio, Inc.
General ticker "PASG" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $26.3M (TTM average)
Passage Bio, Inc. follows the US Stock Market performance with the rate: 3.2%.
Estimated limits based on current volatility of 2.9%: low 4.57$, high 4.93$
Factors to consider:
- Total employees count: 24 (-11.1%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Operating losses, Operational and conduct risks, Clinical trial failure, Regulatory and compliance, Manufacturing risks
- Current price 31.9% below estimated low
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [7.10$, 20.09$]
- 2026-12-31 to 2027-12-31 estimated range: [4.34$, 13.20$]
Financial Metrics affecting the PASG estimates:
- Negative: with PPE of -0.7 at the end of fiscal year the price was high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Industry operating cash flow (median)
- Positive: Investing cash flow per share per price, % of 122.61 > -0.60
- Positive: 19.19 < Shareholder equity ratio, % of 30.11 <= 42.57
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -13.64 <= 0
Short-term PASG quotes
Long-term PASG plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $108.39MM | $70.40MM | $49.30MM |
| Operating Income | $-108.39MM | $-70.40MM | $-49.30MM |
| Non-Operating Income | $6.33MM | $5.63MM | $3.77MM |
| R&D Expense | $61.42MM | $40.18MM | $23.28MM |
| Income(Loss) | $-102.06MM | $-64.77MM | $-45.52MM |
| Net Income(Loss)* | $-102.06MM | $-64.77MM | $-45.52MM |
| Stockholders Equity | $111.28MM | $61.26MM | $18.75MM |
| Assets | $150.54MM | $102.41MM | $62.28MM |
| Operating Cash Flow | $-78.26MM | $-47.96MM | $-31.51MM |
| Capital expenditure | $0.15MM | $0.03MM | $0.00MM |
| Investing Cash Flow | $65.24MM | $54.95MM | $40.22MM |
| Financing Cash Flow | $0.14MM | $8.87MM | $0.02MM |
| Earnings Per Share** | $-37.29 | $-21.44 | $-14.35 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.